MedPath

Bronchial Thermoplasty in Severe Asthma With Frequent Exacerbations

Not Applicable
Conditions
Asthma
Registration Number
NCT02464995
Lead Sponsor
University Hospital, Strasbourg, France
Brief Summary

The purpose of this study is to demonstrate the effectiveness of bronchial thermoplasty in a severe asthmatic population with frequent exacerbations.

This will be a single center randomized and controlled study. Thirty subjects with severe asthma (Gina 4 and 5) with frequent severe exacerbations (four or more bursts of systemic corticosteroids \>3 days each in the previous year) will be randomized 1:1 to either the thermoplasty group (bronchial thermoplasty and medical management) or control group (medical management only).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
34
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Severe exacerbation rate (change from baseline)Baseline, 6 months and 12 months after the last thermoplasty procedure

A severe exacerbation is defined by a burst of systemic corticosteroids \>3 days

Secondary Outcome Measures
NameTimeMethod
Mean oral glucocorticosteroid dose (mg equivalent prednisone)Baseline, 6 and 12 Months
Pre- and post-bronchodilator FEV1Baseline, 6 and 12 Months
Asthma Quality of Life Questionnaire (AQLQ) ScoreBaseline, 3, 6, 9 and 12 Months
Time to the first severe asthma exacerbationanytime
Asthma Control Questionnaire (ACQ) ScoreBaseline, 3, 6, 9 and 12 Months
Structural airway remodeling using CTBaseline and 12 Months
Inflammatory cells and markers in induced sputumTime Frame: Baseline and 12 Months
Mild exacerbation rateBaseline, 6 and 12 Months

Trial Locations

Locations (1)

Hôpitaux Universitaires de Strasbourg

🇫🇷

Strasbourg, France

Hôpitaux Universitaires de Strasbourg
🇫🇷Strasbourg, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.